Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Syngen Biotech Co's Revenue for the
three
months ended in Jun. 2026 was NT$593 Mil. Syngen Biotech Co's average Accounts Receivable for the
three
months ended in Jun. 2026 was NT$370 Mil.
Hence, Syngen Biotech Co's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.61.
Syngen Biotech Co (ROCO:8279) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Syngen Biotech Co Receivables Turnover Related Terms
Syngen Biotech Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Syngen Biotech Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8279 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Syngen Biotech Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syngen Biotech Co Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syngen Biotech Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Syngen Biotech Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syngen Biotech Co (ROCO:8279) has a Receivables Turnover of 1.61 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Syngen Biotech Co and its competitors. According to the industry distribution chart, Syngen Biotech Co ranks #378 out of 847 companies in the Biotechnology industry, placing it in the top 44.6%.
Is Syngen Biotech Co's Receivables Turnover too high?
Syngen Biotech Co's current Receivables Turnover is 1.61. The Biotechnology industry median Receivables Turnover is 5.27. Syngen Biotech Co's value of 1.61 is 69.4% below this industry median. Based on the distribution chart, Syngen Biotech Co ranks #378 out of 847 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Syngen Biotech Co has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngen Biotech Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Syngen Biotech Co ranks #378 out of 847 companies for Receivables Turnover. This puts Syngen Biotech Co in the upper half of its industry. The industry median Receivables Turnover is 5.27. Syngen Biotech Co's value of 1.61 is 69.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syngen Biotech Co's current Receivables Turnover of 1.61 is 69.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Syngen Biotech Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syngen Biotech Co's current Receivables Turnover is 1.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Syngen Biotech Co (ROCO:8279) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$132.99, compared to a current price of NT$84.60 — trading 36.4% below its estimated fair value. The current Receivables Turnover is 1.61 and 69.4% below the Biotechnology industry median of 5.27. Syngen Biotech Co's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Syngen Biotech Co (ROCO:8279), the current Receivables Turnover is 1.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syngen Biotech Co (ROCO:8279) Overvalued in 2026?
Based on GuruFocus' analysis, Syngen Biotech Co stock appears to be undervalued.
The current stock price of NT$84.60 is trading 36.4% below its estimated GF Value™ of NT$132.99.
GuruFocus considers Syngen Biotech Co to be Significantly Undervalued.
Key valuation signals for ROCO:8279:
Receivables Turnover: 1.61
GF Value™: NT$132.99 vs. price of NT$84.60 (36.4% below fair value)
Industry Position: 69.4% below the Biotechnology median (#378 of 847)
No single metric tells the full story. See the ROCO:8279 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syngen Biotech Co Ltd is a biotechnology company. It is engaged in the manufacturing, sales, and trading of microbial pharmaceutical raw materials. It also provides the design and development of health food and biochemical nutrition. The company's products include pharmaceutical ingredients, nutritional ingredients, biology fermentation products, biology agriculture and aquaculture products.
89GF Score
Get the complete analysis for ROCO:8279
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8279 has been successfully added to your 
